{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:04:38Z","timestamp":1784545478961,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BC Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The growing presence of benzodiazepine-adulterated opioids in the unregulated drug supply poses significant challenges for clinicians treating people with opioid use disorder. This commentary highlights key areas of uncertainty and emerging agreement on screening, risk assessment, withdrawal timelines, and treatment approaches for individuals using benzodiazepine-adulterated opioids. It also identifies gaps in community-based support, the effectiveness of drug checking, and the role of medications for opioid use disorder in managing opioid-benzodiazepine withdrawal. Together, these scenarios demonstrate rapidly evolving challenges and the need to refine clinical practices in order to improve care for individuals affected by the evolving unregulated drug supply.<\/jats:p>","DOI":"10.1186\/s13011-026-00747-0","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:22:13Z","timestamp":1784542933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing benzodiazepine dependence arising from use of the adulterated opioid supply: a commentary"],"prefix":"10.1186","volume":"21","author":[{"given":"Gurkiran","family":"Parmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Malette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josey","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Crabtree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"747_CR1","unstructured":"BC Centre on Substance Use. Drug checking results. 2024. Available from: https:\/\/drugsense.bccsu.ubc.ca\/."},{"issue":"6","key":"747_CR2","first-page":"331","volume":"58","author":"College","year":"2016","unstructured":"Doctors of BC, College. New professional standard on safe prescribing. BC Med J. 2016;58(6):331.","journal-title":"BC Med J"},{"issue":"8","key":"747_CR3","first-page":"336","volume":"63","author":"LS Yefet","year":"2021","unstructured":"Yefet LS, Bone J, Courtemanche R, Gill L, Courtmanche D. Opioid prescribing patterns in British Columbia from 2013 to 2017: A population-based study. Br Columbia Med J. 2021;63(8):336\u201342.","journal-title":"Br Columbia Med J"},{"issue":"6","key":"747_CR4","first-page":"320","volume":"60","author":"R Gallagher","year":"2018","unstructured":"Gallagher R. An open, online survey of family physicians on the impact of the standard on the Safe Prescribing of Drugs with Potential for Misuse\/Diversion issued by the college of physicians and Surgeons of BC on managing pain. Br Columbia Med J. 2018;60(6):320\u20131.","journal-title":"Br Columbia Med J"},{"key":"747_CR5","unstructured":"BC Centre on Substance Use. Clinical bulletin: benzodiazepines and opioids. 2021. Available: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2021\/06\/Bulletin-Benzos-and-Opioids.pdf."},{"key":"747_CR6","doi-asserted-by":"crossref","unstructured":"Malette N, Parmar G, Ross J, Crabtree A, Bach P. Approaches for managing benzodiazepine dependence arising from use of the adulterated opioid supply: a Delphi technique. J Addict Med. 2025:10\u20131097.","DOI":"10.1097\/ADM.0000000000001566"},{"key":"747_CR7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1365-2753.2011.01746.x","volume":"17","author":"P Hutchinson","year":"2011","unstructured":"Hutchinson P, Read R. De-mystifying tacit knowing and clues: a comment on Henry et al. Journal of Evaluation in Clinical Practice. J Eval Clin Pract. 2011;17:944\u20137. https:\/\/doi.org\/10.1111\/j.1365-2753.2011.01746.x.","journal-title":"J Eval Clin Pract"},{"key":"747_CR8","doi-asserted-by":"publisher","first-page":"103741","DOI":"10.1016\/j.drugpo.2022.103741","volume":"106","author":"S Klaire","year":"2022","unstructured":"Klaire S, Janssen RM, Olson K, Bridgeman J, Korol EE, Chu T, Ghafari C, Sabeti S, Buxton JA, Lysyshyn M. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada. Int J Drug Policy. 2022;106:103741.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"747_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/jat\/bkab108","volume":"46","author":"A Puzyrenko","year":"2022","unstructured":"Puzyrenko A, Wang D, Schneider R, Wallace G, Schreiber S, Brandt K, Gunsolus IL. Urine drug screening in the era of designer benzodiazepines: comparison of three immunoassay platforms, LC-QTOF-MS and LC-MS-MS. J Anal Toxicol. 2022;46(7):712\u20138.","journal-title":"J Anal Toxicol"},{"issue":"4","key":"747_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/CXA.0000000000000221","volume":"15","author":"MK Laing","year":"2024","unstructured":"Laing MK, Cowan N, Bach P, Giang V. Unanticipated benzodiazepine withdrawal in the context of an adulterated unregulated opioid supply in Vancouver, BC: a case series. Can J Addict. 2024;15(4):32\u201341.","journal-title":"Can J Addict"},{"issue":"9","key":"747_CR11","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/add.15818","volume":"117","author":"KE Torres-Lockhart","year":"2022","unstructured":"Torres-Lockhart KE, Lu TY, Weimer MB, Stein MR, Cunningham CO. Clinical management of opioid withdrawal. Addiction. 2022;117(9):2540\u201350.","journal-title":"Addiction"},{"issue":"6","key":"747_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/NND.0000000000000176","volume":"31","author":"K Berl","year":"2015","unstructured":"Berl K, Collins ML, Melson J, Mooney R, Muffley C, Wright-Glover A. Improving nursing knowledge of alcohol withdrawal: second generation education strategies. J Nurses Prof Dev. 2015;31(6):328\u201332.","journal-title":"J Nurses Prof Dev"},{"issue":"1","key":"747_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13063-024-08692-8","volume":"26","author":"F Chalabianloo","year":"2025","unstructured":"Chalabianloo F, Fadnes LT, Assmus J, Mordal J, Solli KK, Dale KS, Andersen CD, Zavenova S, R\u00f8nning BH, Blomkvist AW. Benzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: study protocol for the randomized controlled trial BMX-BAR. Trials. 2025;26(1):2.","journal-title":"Trials"},{"key":"747_CR14","doi-asserted-by":"crossref","unstructured":"Power N, Archambault L, Perreault M. New challenges and opportunities for opioid agonist treatment access and retention: a scoping review. J Drug Issues. 2024;00220426241269828.","DOI":"10.1177\/00220426241269828"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-026-00747-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-026-00747-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-026-00747-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:22:15Z","timestamp":1784542935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13011-026-00747-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1186\/s13011-026-00747-0","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have provided consent for this work to be published.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"50"}}